Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine

Joel E. Gallant, Richard D Moore, Jeanne C Keruly, Douglas D. Richman, Richard E. Richman, Richard E Chaisson

Research output: Contribution to journalArticle

Abstract

To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and ≤250 CD4 cells/mm3following initiation of zidovudine were analyzed. Of these patients, 336 (32%) received regular acyclovir (≥6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or <100 CD4 cells/mm3at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P =.057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.

Original languageEnglish (US)
Pages (from-to)346-352
Number of pages7
JournalJournal of Infectious Diseases
Volume172
Issue number2
DOIs
StatePublished - 1995

Fingerprint

Acyclovir
Zidovudine
Virus Diseases
HIV
Survival
AIDS-Related Complex
Acquired Immunodeficiency Syndrome
Mortality
Herpesviridae Infections
Simplexvirus

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. / Gallant, Joel E.; Moore, Richard D; Keruly, Jeanne C; Richman, Douglas D.; Richman, Richard E.; Chaisson, Richard E.

In: Journal of Infectious Diseases, Vol. 172, No. 2, 1995, p. 346-352.

Research output: Contribution to journalArticle

@article{40ef4cf0c26a4006a6c563e47bb89d86,
title = "Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine",
abstract = "To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and ≤250 CD4 cells/mm3following initiation of zidovudine were analyzed. Of these patients, 336 (32{\%}) received regular acyclovir (≥6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or <100 CD4 cells/mm3at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P =.057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.",
author = "Gallant, {Joel E.} and Moore, {Richard D} and Keruly, {Jeanne C} and Richman, {Douglas D.} and Richman, {Richard E.} and Chaisson, {Richard E}",
year = "1995",
doi = "10.1093/infdis/172.2.346",
language = "English (US)",
volume = "172",
pages = "346--352",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine

AU - Gallant, Joel E.

AU - Moore, Richard D

AU - Keruly, Jeanne C

AU - Richman, Douglas D.

AU - Richman, Richard E.

AU - Chaisson, Richard E

PY - 1995

Y1 - 1995

N2 - To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and ≤250 CD4 cells/mm3following initiation of zidovudine were analyzed. Of these patients, 336 (32%) received regular acyclovir (≥6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or <100 CD4 cells/mm3at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P =.057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.

AB - To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and ≤250 CD4 cells/mm3following initiation of zidovudine were analyzed. Of these patients, 336 (32%) received regular acyclovir (≥6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or <100 CD4 cells/mm3at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P =.057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.

UR - http://www.scopus.com/inward/record.url?scp=0029125606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029125606&partnerID=8YFLogxK

U2 - 10.1093/infdis/172.2.346

DO - 10.1093/infdis/172.2.346

M3 - Article

VL - 172

SP - 346

EP - 352

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -